Neuraxis Inc
NRXS2.500USD
0.000
Market hours （ET）Quotes delayed by 15 min
18.04MMarket Cap
LossP/E TTM
More Details of Neuraxis Inc Company
Neuraxis, Inc. is a medical technology company focused on developing neuromodulation therapies to address chronic and debilitating conditions in children and adults. It is engaged in advancing science with its IB-Stim therapy, based on its Percutaneous Electrical Nerve Field Stimulation (PENFS) technology, which was developed internally by the Company. The Company's first product, IB-Stim, is a PENFS system intended to be used in patients 11-18 years of age with functional abdominal pain associated with IBS. The IB-Stim is intended to be used for 120 hours per week for three consecutive weeks, and not to exceed four weeks, through application to branches of Cranial Nerves V, VII, IX and X, and the occipital nerves identified by transillumination, as an aid in the reduction of pain when combined with other therapies for IBS. Other indications in its pipeline are comprised of functional nausea in children, post-concussion syndrome in children, and cyclic vomiting syndrome in children.
Company Info
Ticker SymbolNRXS
Company nameNeuraxis Inc
IPO dateAug 09, 2023
CEOMr. Brian Carrico
Number of employees21
Security typeOrdinary Share
Fiscal year-endAug 09
Address11611 N. Meridian St
CityCARMEL
Stock exchangeNYSE American Consolidated
CountryUnited States of America
Postal code46032
Phone18126890791
Websitehttps://neuraxis.com/
Ticker SymbolNRXS
IPO dateAug 09, 2023
CEOMr. Brian Carrico
Company Executives
Name
Name/Position
Position
Shareholding
Change
Dr. Christopher Robin (Chris) Brown
Dr. Christopher Robin (Chris) Brown
Director - Innovation, Founder, Director
Director - Innovation, Founder, Director
792.84K
--
Mr. Brian Carrico
Mr. Brian Carrico
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
20.12K
--
Ms. Kristin A. Ferge
Ms. Kristin A. Ferge
Independent Director
Independent Director
14.34K
+1112.17%
Mr. Dan Clarence
Mr. Dan Clarence
Chief Operating Officer
Chief Operating Officer
--
--
Mr. Timothy R. Henrichs
Mr. Timothy R. Henrichs
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Thomas Carrico
Dr. Thomas Carrico
Chief Regulatory Officer, Compliance Officer and Privacy Officer
Chief Regulatory Officer, Compliance Officer and Privacy Officer
--
--
Ms. Beth Keyser
Ms. Beth Keyser
Independent Director
Independent Director
--
--
Mr. Gil Aharon
Mr. Gil Aharon
Director
Director
--
--
Dr. Adrian Miranda
Dr. Adrian Miranda
Chief Medical Officer, Senior Vice President - Science and Technology
Chief Medical Officer, Senior Vice President - Science and Technology
--
-100.00%
Mr. Bradley Mitch Watkins
Mr. Bradley Mitch Watkins
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Name
Name/Position
Position
Shareholding
Change
Dr. Christopher Robin (Chris) Brown
Dr. Christopher Robin (Chris) Brown
Director - Innovation, Founder, Director
Director - Innovation, Founder, Director
792.84K
--
Mr. Brian Carrico
Mr. Brian Carrico
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
20.12K
--
Ms. Kristin A. Ferge
Ms. Kristin A. Ferge
Independent Director
Independent Director
14.34K
+1112.17%
Mr. Dan Clarence
Mr. Dan Clarence
Chief Operating Officer
Chief Operating Officer
--
--
Mr. Timothy R. Henrichs
Mr. Timothy R. Henrichs
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Thomas Carrico
Dr. Thomas Carrico
Chief Regulatory Officer, Compliance Officer and Privacy Officer
Chief Regulatory Officer, Compliance Officer and Privacy Officer
--
--
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholding Stats
Updated: Sun, Jul 27
Updated: Sun, Jul 27
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Hannasch (Brian)
14.45%
Brown (Christopher Robin)
10.12%
Creative Planning, Inc.
7.04%
AIGH Capital Management, LLC.
3.80%
Parsons Capital Management, Inc.
1.49%
Other
63.10%
Shareholders
Shareholders
Proportion
Hannasch (Brian)
14.45%
Brown (Christopher Robin)
10.12%
Creative Planning, Inc.
7.04%
AIGH Capital Management, LLC.
3.80%
Parsons Capital Management, Inc.
1.49%
Other
63.10%
Shareholder Types
Shareholders
Proportion
Individual Investor
25.70%
Investment Advisor/Hedge Fund
7.69%
Private Equity
3.80%
Investment Advisor
2.28%
Bank and Trust
1.36%
Hedge Fund
0.37%
Other
58.80%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
29
3.33M
43.07%
+663.50K
2025Q1
31
4.67M
62.21%
+933.75K
2024Q4
29
4.04M
56.27%
+476.54K
2024Q3
28
3.89M
54.36%
+476.60K
2024Q2
27
3.62M
51.12%
+229.93K
2024Q1
18
1.89M
32.23%
+1.25M
2023Q4
18
2.14M
36.50%
+1.56M
2023Q3
14
2.07M
34.17%
+2.07M
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Hannasch (Brian)
700.97K
8.95%
-75.00K
-9.67%
Jun 30, 2025
Brown (Christopher Robin)
792.84K
10.12%
--
--
Mar 31, 2025
Creative Planning, Inc.
551.67K
7.04%
+551.67K
--
Mar 31, 2025
AIGH Capital Management, LLC.
19.87K
0.25%
+19.87K
--
Mar 31, 2025
Parsons Capital Management, Inc.
116.73K
1.49%
--
--
Mar 31, 2025
BMO Harris Bank N.A.
106.48K
1.36%
-32.54K
-23.41%
Mar 31, 2025
The Vanguard Group, Inc.
27.98K
0.36%
--
--
Mar 31, 2025
Citadel Advisors LLC
26.82K
0.34%
-20.27K
-43.05%
Mar 31, 2025
Stifel, Nicolaus & Company, Incorporated
25.71K
0.33%
--
--
Mar 31, 2025
Geode Capital Management, L.L.C.
24.97K
0.32%
+2.27K
+9.98%
Mar 31, 2025
View more
Related ETFs
Name
Proportion
No Data
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
